The PEGylated Proteins Market is primarily driven by the growing demand for effective drug delivery systems, particularly in the treatment of chronic diseases such as cancer, hepatitis, and rheumatoid ...

Havas Health named Anna Maria Marra as CEO of Europe on Tuesday morning, a role in which she will lead and oversee all ...

Target patient enrollment of 92 evaluable patients achieved in the VIRAGE Phase 2b clinical trial of VCN-01 in patients with metastatic ...

The research also highlights potential avenues for repurposing existing drugs. Researchers found that trimethoprim and sulfamethoxazole, antibiotics used to treat ... funding from Calico Life Sciences ...

Both the FDA and EMA previously granted fast track and orphan drug designations to VCN-01 for the treatment ... Placed second of five finalists for Merck KGaA's EMEA Advance Biotech Grant which ...

After Alexander Fleming’s initial discovery of the penicillium mould’s antibiotic ... collaboration including Merck, Pfizer and Squibb worked on mass producing the drug during World War ...

The global urinary antibacterial and antiseptic pharmaceuticals market is projected to grow at a robust Compound Annual Growth Rate (CAGR) of 4.3% during the forecast period, driven by increasing ...

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront ...

Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...